The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Open accessAbstract
BACKGROUND & AIM: homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. A randomized controlled trial, including 38 centers from 12 European countries, evaluated the safety and efficacy of three doses of oral norUDCA (500mg/d, 1,000mg/d or 1,500mg/d) compared with placebo in patients with PSC. METHODS: One hundred sixty-one PSC patients without concomitant UDCA therapy and with elevated serum alkaline phosphatase (ALP) levels were randomized for a 12-week treatment followed by a 4-week follow-up. The primary efficacy endpoint was the mean relative change in ALP levels between baseline and end of treatment visit. RESULTS: norUDCA reduced ALP levels by -12.3%, -17.3%, and -26.0% in the 500, 1,000, and 1,500mg/d groups (p=0.029, p=0.003, and p<0.0001 when compared to placebo), respectively, while a +1.2% increase was observed in the placebo group. Similar dose-dependent results were found for secondary endpoints, such as ALT, AST, γ-GT, or the rate of patients achieving ALP levels <1.5× ULN. Serious adverse events occurred in seven patients in the 500mg/d, five patients in the 1,000mg/d, two patients in the 1500mg/d group, and three in the placebo group. There was no difference in reported pruritus between treatment and placebo groups. CONCLUSIONS: norUDCA significantly reduced ALP values dose-dependently in all treatment arms. The safety profile of norUDCA was excellent and comparable to placebo. Consequently, these results justify a phase III trial of norUDCA in PSC patients. Lay summary: Effective medical therapy for primary sclerosing cholangitis (PSC) is urgently needed. In this phase II clinical study in PSC patients, a side chain-shortened derivative of ursodeoxycholic acid, norursodeoxycholic acid (norUDCA), significantly reduced serum alkaline phosphatase levels in a dose-dependent manner during a 12-week treatment. Importantly, norUDCA showed a favorable safety profile, which was similar to placebo. The use of norUDCA in PSC patients is promising and will be further evaluated in a phase III clinical study. ClinicalTrials.gov number: NCT01755507.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinically, norUDCA improved biochemical markers of cholestasis in a recent phase 2 clinical trial in PSC irrespective of prior exposure and response to UDCA212”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
A Stagewise Rejective Multiple Test Procedure Based on a Modified Bonferroni Test
Hommel, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics
Hofmann, A. F., & Hagey, L. R. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7568-6 · Cited by 873
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 612
Adaptive Sample Size Calculations in Group Sequential Trials
Lehmacher, W., & Wassmer, G. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01286.x · Cited by 599
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Self-citationACG clinical guideline: primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., & Harrison, E. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.112 · Cited by 524
Cited by
Sorted by citations
Items 201–298 of 298
Treatment of Primary Sclerosing Cholangitis Including Transplantation
Wheless, W. H., & Russo, M. W. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.07.008 · Cited by 5
Woo, S. H., Lee, S., Moon, S., Han, J., Seo, K.-S., Lee, H., Lee, C., & Hwang, J. H. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122342 · Cited by 4
Paik, W. H., Park, J. K., Chung, M. J., Huh, G., Park, C. H., Lee, S. H., Jeong, H. S., Kim, H. J., & Park, D. H. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0629 · Cited by 5
Novel Bile Acid Therapies for Liver Disease.
Karpen, S. J. (2018) · Europe PMC (PubMed Central) · Cited by 4
Clinical Trials in PBC Going Forward
Corpechot, C. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1687852 · Cited by 5
Losurdo, G., Gravina, A. G., Maroni, L., Gabrieletto, E. M., Ianiro, G., Ferrarese, A., Visintin, A., Frazzoni, L., Pellegatta, G., Sessa, A., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.08.008 · Cited by 4
Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease
Okada, H., Sugimoto, S., Kayashima, A., Mikami, Y., Kanai∥, T., Nakamoto, N., Collaborators, K. P., Yoshimatsu, Y., Kiyohara, H., Nakadai, Y., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02388-3 · Cited by 3
Current and future opportunities for the management of primary biliary cholangitis
Naffouj, S., & Wang, J. R. (2023) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2023.1241901 · Cited by 5
Recent Insights into Pediatric Primary Sclerosing Cholangitis
Stevens, J. P., & Gupta, N. A. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.03.009 · Cited by 9
Current trends and future perspectives in the treatment of PBC and PSC: A review
Das, D. D., Sharma, N., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100065 · Cited by 4
Bile acid therapy for primary biliary cholangitis: Pathogenetic validation
Reshetnyak, V. I., & Maev, I. V. (2024) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i1.101771 · Cited by 3
Review of pharmacotherapeutic treatments for primary sclerosing cholangitis
Zhang, C., Hussaini, T., & Yoshida, E. M. (2019) · Canadian Liver Journal · doi:10.3138/canlivj-2018-0016 · Cited by 3
Adverse events of ursodeoxycholic acid: a real-world pharmacovigilance study using FAERS (2004–2023)
Ni, Y., Guan, X., Gao, X., Wang, Y., Qin, D., Shan, Z., & Wang, N. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1574308 · Cited by 2
Wang, K., Shi, L., Li, X., Li, W., Wang, B., Zhou, S., Cao, B., & Zheng, P. (2026) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2026.105003 · Cited by 2
Jalan‐Sakrikar, N., Anwar, A. A., Ali, A., Nasser‐Ghodsi, N., Felzen, A., Huebert, R. C., LaRusso, N. F., & O’Hara, S. P. (2026) · Physiological Reviews · doi:10.1152/physrev.00022.2025 · Cited by 5
Ursodeoxycholic acid derivative: safe and effective
Dickson, I. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.84 · Cited by 2
Shahramian, I., Bazı, A., Mostafaee, R., & Mohammadi, M. H. (2020) · Pharmaceutical Sciences · doi:10.34172/ps.2019.62 · Cited by 2
Usoltseva, O. V., Surkov, A. N., Movsisyan, G. B., Потапов, А. С., Kulebina, E. A., Алексеевич, К. К., & Черников, В. В. (2022) · Вопросы современной педиатрии · doi:10.15690/pf.v19i2.2407 · Cited by 2
Hepatobiliary Involvement in Cystic Fibrosis
Bertolini, A., Bodewes, F. A. J. A., Slae, M., & Wilschanski, M. A. (2020) · Respiratory medicine · doi:10.1007/978-3-030-42382-7_14 · Cited by 2
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 3
Alvarado, A. (2018) · Clinical Research and Trials · doi:10.15761/crt.1000241 · Cited by 2
Pathophysiologic Basis for Alternative Therapies for Cholestasis
Fuchs, C. D., Halilbasic, E., & Trauner, M. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch30 · Cited by 2
Hameed, H., Irshad, N., Yousaf, M. A., Mumtaz, S., & Sohail, M. I. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01226-8 · Cited by 1
Primary sclerosing cholangitis and IgG4-associated cholangitis
Bowlus, C. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00020-5 · Cited by 1
Wastewater Treatment in Microalgae Cultivation Systems: Recommendations for Large-Scale Application
Farias, S. L., Ruas, G., Boncz, M. Á., de Oliveira, F. R., Lütterbeck, C. A., Machado, Ê. L., & Filho, F. J. C. M. (2025) · Grand challenges in biology and biotechnology · doi:10.1007/978-3-031-84282-5_12 · Cited by 1
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
Tatscher, E., Mady, S., & Fickert, P. (2025) · Seminars in Liver Disease · doi:10.1055/a-2601-9426 · Cited by 1
Trampert, D. C. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.018 · Cited by 1
Orlandi, G., Overi, D., Tinco, R. D., Pisciotta, A., Bertani, G., Biasi, S. D., Leone, S., Cardinale, V., Franchitto, M., Miglietta, S., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101903 · Cited by 1
Primary Sclerosing Cholangitis
Hussain, N., & Trivedi, P. J. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.013 · Cited by 1
“Overlap” Syndromes in Autoimmune Liver Disease
Tzadok, R., & Houri, I. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.008 · Cited by 1
Fuchs, C. D., Petrenko, O., Mlitz, V., Dixon, E. D., Scharnagl, H., Ghallab, A., Reiberger, T., Garfinkel, B. P., & Trauner, M. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00071-1 · Cited by 1
Immunomodulatory mechanisms of bile acids in autoimmune diseases along the gut-liver axis
Zhang, S., Xiong, X., Wei, S., Meng, R., An, H., & Chen, L. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104183 · Cited by 1
[Apolipoprotein B and small, dense LDL-C].
Ito, Y. (2012) · PubMed · Cited by 1
Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients
McCain, J. D., Chascsa, D. M. H., & Lindor, K. D. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1898370 · Cited by 1
Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Bagriy, A. E., Zubov, A. D., Khomenko, M. V., Михайличенко, Е. С., Пылаева, Е. А., Khaustova, N. A., & Bryukhovetskaya, E. V. (2021) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-2-14-26 · Cited by 1
Primary Sclerosing Cholangitis: A Clinical Update
Sundaram, S., & Jearth, V. (2019) · European Medical Journal · doi:10.33590/emj/10313809 · Cited by 1
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis
Pham, H. N., Pham, L., & Sato, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2362263 · Cited by 1
Primary sclerosing cholangitis
Ahmad, J., & Grewal, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00019-5 · Cited by 1
Neues zur adjuvanten Therapie der Gallengangsatresie nach Kasai-Hepatoportoenterostomie
Madadi‐Sanjani, O., Hegen, B., Oh, J. S., Reinshagen, K., & Tomuschat, C. (2024) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-024-02093-6 · Cited by 1
Panuganti, V. K., Alluri, C. V., Dundigalla, M. R., Mohammad, J., Madala, P. K., & V., S. K. S. S. V. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/6613969 · Cited by 1
Primary Sclerosing Cholangitis
Sangha, S., & Bowlus, C. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-285-8_56 · Cited by 1
Dupas, J., Ho, N. F. H., & Hofmann, A. F. (2018) · Lipids · doi:10.1002/lipd.12052 · Cited by 1
Primary Sclerosing Cholangitis
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_5 · Cited by 1
Primary Sclerosing Cholangitis
Bowlus, C. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_25 · Cited by 1
Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
Gao, W., Li, Z., Chu, H., Yuan, H., Hu, L., Yao, L., Zhang, L. R., Wang, W., Lin, R., & Yang, L. (2022) · Springer eBooks · doi:10.1007/978-981-19-2615-0_6 · Cited by 1
Nicht-alkoholische Fettlebererkrankung als Komorbidität chronischer Lebererkrankungen
Käser, R., & Böttler, T. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_26 · Cited by 1
Diagnostic workup of suspected hereditary cholestasis in adults: a case report
Dröge, C., Götze, T., Behrendt, A., Gohlke, H., & Keitel, V. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00016 · Cited by 1
Tse, C. S., Loftus, E. V., Raffals, L. E., Gossard, A. A., & Lightner, A. L. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14907 · Cited by 1
Effective medical treatments for PSC needed ASAP - is AESOP the answer?
Trauner, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.009 · Cited by 1
Zhu, C., Boucheron, N., Rîca, R., Stolz, V., Halilbasic, E., Claudel, T., Al-Rubaye, O., Lercher, A., Baumgartner, M., Sandner, L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.10.479975 · Cited by 1
Primär sklerosierende Cholangitis
Weismüller, T. J., & Strassburg, C. P. (2018) · Die Gastroenterologie · doi:10.1007/s11377-018-0250-0
篤, 田. (2018) · 胆道 · doi:10.11210/tando.32.241
Emerging therapeutic targets for primary sclerosing cholangitis
Kalani, A., Tabibian, J. H., & Lindor, K. D. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1490643
Cirrhosis and Autoimmune Liver Disease
Stirnimann, G., Ebadi, M., Mason, A. L., & Montaño‐Loza, A. J. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00449-1
Verbesserte Prognose, aber limitierte Therapieoptionen für PBC und PSC
Koenen, M. T., Zimmermann, H. W., & Trautwein, C. (2019) · Gastro-News · doi:10.1007/s15036-019-0633-1
Bile Acids and Bilirubin in Liver Immunology
Zhu, C., Claudel, T., & Trauner, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_7
Low Phospholipid-Associated Cholelithiasis (LPAC)
Floreani, A., & Corpechot, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-65908-0_7
Li, J., Truong, J. K., Pachura, K. J., Rao, A., Gambeer, S., Fuchs, C. D., Karpen, S. J., Trauner, M. A., & Dawson, P. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.06.430841
Marín, J. D. M., Riveros, S. C. H., & Garzón-Olarte, M. (2021) · Hepatología · doi:10.52784/27112330.140
Kamp, E. J. C. A., Vries, A. C. D., & Bruno, M. J. (2019) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.65878-6
Primär sklerosierende Cholangitis
Weismüller, T. J. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23847-5.00053-3
Recent Findings in the Gut-Liver Axis and Associated Disease Therapy
Humphry, N. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/10154221
Burghart, L. (2023) · rheuma plus · doi:10.1007/s12688-023-00628-5
Weltzsch, J. P., Sebode, M., & Hartl, J. (2023) · Die Gastroenterologie · doi:10.1007/s11377-023-00725-z
Primär sklerosierende Cholangitis
Weismüller, T. J. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21005-1.00056-1
Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders
Alrehaili, B. D. (2024) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_53_24
Leighton, J., Jones, D. E., Dyson, J. K., & Cordell, H. J. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01927-2
He, Y., He, H., Qi, L., & Xie, Y. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0239
Shi, Z., Wang, B., Wang, S., Tan, H., He, J., Zhang, W., & Lin, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5270121
Physiopathologie de la cholestase
Tordjmann, T. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(24)59730-3
Heeren, J., Evangelakos, I., Verkade, E., Kuipers, F., Rohde, J. S., Heine, M., Worthmann, A., Graute, S., Fuh, M. M., Gunasekaran, K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8280795/v1
Leighton, J., Jones, D. E. J., Dyson, J. K., & Cordell, H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26019707
Leighton, J., Jones, D. E. J., Dyson, J. K., & Cordell, H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26732416
Additional file 1 of Quality of life in primary sclerosing cholangitis: a systematic review
Marcus, E., Stone, P., Krooupa, A.-M., Thorburn, D., & Vivat, B. (2021) · Figshare · doi:10.6084/m9.figshare.14253837
Leighton, J., Jones, D. E. J., Dyson, J. K., & Cordell, H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26019517
Stremmel, W., & Weiskirchen, R. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.158
Immunpathogenese und Therapie der Primär Sklerosierenden Cholangitis
Zecher, B. F., & Schramm, C. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2730-4719 · Cited by 1
Yuan, Z., Wang, J., Zhang, H., Miao, Y., Chai, Y., Li, A., Tang, Q., Chen, Q., Zhang, L., Yu, Q., et al. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104306
Kumar, K. S., Saraswat, V. A., Kumar, A., Kulkarni, A. V., Goel, A., Shalimar, Shukla, A., Duseja, A. K., Dhiman, R. K., & Aggarwal, R. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103536
Acides biliaires totaux et grossesse
Émile, C. (2026) · Option/Bio · doi:10.1016/s0992-5945(26)74963-1
Evangelakos, I., Verkade, E., Rohde, J. K., Zaufel, A., Vargek, M., Heine, M., Worthmann, A., Graute, S., Fuh, M. M., Gunasekaran, K., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102363
Influence of bile acids metabolism on hepatic immunity in mice
Guinot, V. (2022) · theses.fr (ABES) · doi:10.70675/b69bb11eza30fz4874z9af2za6e31b2d5ad8
Wu, Q., Gao, L.-Y., Feng, H., Liu, H.-L., Gao, H., Peng, W., & Li, N. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1797381
Beyond the Graft: Optimizing Post-Transplant Care in Primary Sclerosing Cholangitis
Becchetti, C., Viganò, R., Aprile, F., Scaravaglio, M., Vitale, G., Perricone, G., Mazzarelli, C., Vangeli, M., Belli, L. S., Carbone, M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093480
Bertin, L., Henderson, P., Pollok, R. C. G., Queiroz, N., Fabris, L., Savarino, E. V., Rodríguez-Lago, I., & Barberio, B. (2026) · JCC Plus · doi:10.1002/jcc5.70039
Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review
Malakar, S., Sood, N., Giri, S., & Samanta, A. (2026) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.120122
Bandyopadhyay, S., Samajdar, S. S., Mukherjee, S., & Joshi, S. (2026) · World Journal of Hepatology · doi:10.4254/wjh.118548
Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review
Cao, G., Zhao, H., Lin, G., Chen, J., Gao, C., Méndez‐Sánchez, N., Gao, F., & Qi, X. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03696-z
Primary Sclerosing Cholangitis in Children
Kavarian, P., & Miethke, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.08.003
Bile acid-based therapeutics: recent advances in bile acid conjugates and derivatives
Seo, M., Lee, J.-H., Yang, S.-B., Ma, G., Lee, H., Han, J., Ryu, Y., & Park, J. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00830-5
Bile acid signaling in health and disease
Fan, Z., He, M., Liang, T., 张必利, Zhao, N., & Li, P. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00603-4
Wang, X., Zhang, T., Ren, Z., & Ju, B. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1972466
Zhu, H., Chen, H., Gong, Q., Chen, Z., Zhang, C., Xu, J., & Wang, T. (2026) · Medicinal Research Reviews · doi:10.1002/med.70116
Primary and Secondary Sclerosing Cholangitis
Tan, N., & Hirschfield, G. M. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch21
Crosstalk along the gut–liver axis in liver disease: Clinical and mechanistic aspects
Nakamoto, N., Okada, H., Bäckhed, F., Schnabl, B., & Hov, J. R. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.10.019
Metadata
- Authors
- Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., Schrumpf, E., Nevens, F., Trivedi, P., Reiter, F. P., Tornai, I., Halilbasic, E., Greinwald, R., Pröls, M., Manns, M. P., & Trauner, M.
- Affiliations
- Medical University of Graz (AT)
- University of Birmingham (GB)
- LMU Klinikum (DE)
- University of Gothenburg (SE)
- University of Helsinki (FI)
- University Medical Center Hamburg-Eppendorf (DE)
- University of Bonn (DE)
- John Radcliffe Hospital (GB)
- Karolinska University Hospital (SE)
- Oslo University Hospital (NO)
- KU Leuven (BE)
- Medical University of Vienna (AT)
- Dr Falk Pharma (Germany) (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Trauner, Michael
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 67
- Issue
- 3
- Pages
- 549-558
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2616282068
- Cited by
- 297
- References
- 45
- Citations by year
- 2026: 30 · 2025: 22 · 2024: 38 · 2023: 25 · 2022: 35 · 2021: 43 · 2020: 36 · 2019: 29 · 2018: 28 · 2017: 9
- FWCI
- 17.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, cc-by-nc-nd)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- Funders
- Falk Foundation
- Pfizer
- Gilead Sciences
- National Institute for Health and Care Research
- Astellas Pharma
- Dr. Falk Pharma
- Cilag
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary sclerosing cholangitis, cholestasis, alkaline phosphatase, dose-dependent effects, safety profile, pruritus, liver fibrosis
- MeSH terms
- Adult, Alkaline Phosphatase, Cholestasis, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Ursodeoxycholic Acid, Cholangitis, Sclerosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
